Please assess the completion status of the following clinical trial:

Trial Title: A Study for Patients With Acute Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Dose escalation period for both schedules:~* Participants must have a confirmed diagnosis of acute leukemia regardless of sub-type and for whom experimental Phase 1 therapy is appropriate.~* Are greater than or equal to 18 years of age.~* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale.~* Females with childbearing potential must have had a negative urine or serum pregnancy test less than or equal to 7 days prior to the first dose of study drug.~Dose confirmation period for both schedules:~* Participant must have a confirmed diagnosis of untreated acute myeloblastic leukemia (AML), should not be a candidate for standard therapy, and a clinical trial is a preferred treatment option or have acute AML that is relapsed or refractory to no more than 2 prior induction regimens. Hydroxyurea to control prior blast counts is not considered a prior regimen.~* Are greater than or equal to 60 years of age.~* Have a performance status of 0 or 1 on the ECOG scale.~* Females with childbearing potential must have had a negative urine or serum pregnancy test less than or equal to 7 days prior to the first dose of study drug.~Exclusion Criteria:~* Have received treatment within 28 days of the initial dose of study drug with a drug that has not received regulatory approval for any indication.~* Participants with known central nervous system (CNS) leukemia by spinal fluid cytology or imaging. A lumbar puncture is not required unless CNS involvement is clinically suspected. Participants with signs or symptoms of leukemic meningitis or a history of leukemic meningitis must have a negative lumbar puncture within 2 weeks of study enrollment.~* Have other active malignancy (with the exception of basal and squamous cell skin cancer) at time of study entry.~* Have had an autologous or allogenic bone marrow transplant within 3 months. All organ toxicity must be resolved.~* Have evidence of graft-versus-host disease due to an allogenic bone marrow transplant.~* Have uncontrolled systemic infection.~* Females who are pregnant or lactating.~* Have known positive test results in human immunodeficiency virus (HIV), hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb) (screening not required).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2523355 on Days 1, 2, and 3 (Type: EXPERIMENTAL): Starting dose was 2 milligrams per meter squared (mg/m\^2) administered by a 1-hour intravenous (IV) infusion on Days 1, 2, and 3 of every 21-day Cycle.
- LY2523355 on Days 1, 5, and 9 (Type: EXPERIMENTAL): Starting dose was 8 milligrams per meter squared (mg/m\^2) administered by a 1-hour IV infusion over 1 hour on Days 1, 5, and 9 of every 21-day Cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy